ESTRO 2022 - Abstract Book

S771

Abstract book

ESTRO 2022

score 1 vs. 2-4 at baseline, median (IQR) estimated risk of Xer3-4 were 0.50 (0.44-0.80) and 0.76 (0.61-0.79). The corresponding observed rates of Xer3-4 in the two groups were 52% and 75%.

Conclusion Six months after treatment the majority of patients reported moderate to severe xerostomia. The closed testing procedure resulted in an intercept update of the original model. The original model underestimated the risk of moderate to severe xerostomia, whereas the validated model was well-calibrated and had good discriminative ability.

Mini-Oral: 22: AI, big data, automation

MO-0883 Proton Beam Therapy for Central Nervous System tumours: outcomes from the Proton Overseas Programme

S. Gaito 1,2 , E. Hwang 3,4 , A. France 1 , G. Whitfield 3,2 , S. Pan 5 , G. Price 2 , M. Aznar 2 , A. Crellin 6 , D. Indelicato 7 , E. Smith 3,1,2

1 The Christie NHS Foundation Trust, Proton Clinical Outcomes Unit, Manchester, United Kingdom; 2 University of Manchester, Manchester Cancer Research Centre, Manchester, United Kingdom; 3 The Christie NHS Foundation Trust, The Christie Proton Beam Therapy Centre, Manchester, United Kingdom; 4 Institute of Medical Physics, School of Physics, University of Sidney, Australia; 5 The Christie NHS Foundation Trust, The Christie Proton Beam Therapy centre, Manchester, United Kingdom; 6 NHS England, National Clinical Lead Proton Beam Therapy, Manchester, United Kingdom; 7 University of Florida, Department of Radiation Oncology, Jacksonville, USA Purpose or Objective In 2008, the UK National Health Service (NHS) started the Proton Overseas Programme (POP), to provide access for Proton Beam Therapy (PBT) abroad for selected tumour diagnoses, whilst two national centres were being planned. This work reports the moderate-severe toxicities and their incidence in the patient group treated for Central Nervous System (CNS) malignancies.

Materials and Methods